多形性胶质母细胞瘤治疗药(GBM)市场:现状分析与预测(2022-2030年)

多形性胶质母细胞瘤 (GBM) 是一种侵袭性脑肿瘤，由神经胶质细胞产生，神经胶质细胞是支持和保护大脑神经细胞的细胞。它是最常见的恶性原发性脑肿瘤，约占所有脑肿瘤的15%。多形性胶质母细胞瘤患病率的增加是推动多形性胶质母细胞瘤治疗市场增长的关键因素。例如，根据国家脑肿瘤协会的数据，GBM 占所有原发性恶性脑肿瘤的 49.1%。据估计，美国每年有超过 10,000 人死于胶质母细胞瘤。

为了更好地了解行业市场采用情况，市场分为北美（美国、加拿大、北美其他地区）、欧洲（德国、英国、法国、意大利、西班牙、欧洲其他地区）、亚太地区（中国） 、日本，根据印度、韩国、澳大利亚和亚太地区其他国家/地区的全球影响力进行分析）、世界其他地区。北美已成为治疗多形性胶质母细胞瘤的重要市场。这主要是由于胶质母细胞瘤的高患病率以及该地区现有的基础设施，从而促进了该地区多形性胶质母细胞瘤治疗的显着增长。该地区越来越多的人正在寻求替代和补充疗法来补充其传统医疗保健，并引入了医疗补贴来控制医疗费用。此外，该地区提供综合疗法的医院数量不断增加也是该地区市场增长的一个因素。例如，根据美国脑肿瘤协会的数据，到 2022 年，将有超过 13,000 名美国人被诊断出患有多形性胶质母细胞瘤。

目录

第1章 市场简介

• 市场定义
• 主要目的
• 相关利益者
• 限制事项

第2章 调查手法或前提

• 调查流程
• 调查手法
• 受访者简介

第3章 市场摘要

第4章 摘要整理

第5章 COVID-19对全球多形性胶质母细胞瘤治疗(GBM)市场带来的影响

第6章 全球多形性胶质母细胞瘤治疗(GBM)的市场收益，2020-2028年

第7章 市场洞察:各治疗法

• 手术
• 放射治疗
• 化疗
• 标靶治疗
• 肿瘤治疗领域(TTF)疗法
• 免疫疗法

第8章 市场洞察:各最终用途

• 医院
• 诊所
• 门诊病人手术中心
• 其他

第9章 市场洞察:各地区

• 北美的多形性胶质母细胞瘤治疗(GBM)市场
  • 美国
  • 加拿大
  • 其他北美地区
• 欧洲的多形性胶质母细胞瘤治疗(GBM)市场
  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙
  • 其他欧洲地区
• 亚太地区的多形性胶质母细胞瘤治疗(GBM)市场
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
  • APAC的其他各国
• 其他地区的多形性胶质母细胞瘤治疗(GBM)市场

第10章 多形性胶质母细胞瘤治疗(GBM)市场动态

• 推动市场要素
• 市场课题
• 影响分析

第11章 多形性胶质母细胞瘤治疗(GBM)市场机会

第12章 多形性胶质母细胞瘤治疗(GBM)市场趋势

第13章 需求面和供给面的分析

• 需求面分析
• 供给面分析

第14章 价值链分析

第15章 价格分析

第16章 策略性洞察能力

第17章 竞争模式

• 竞争情形
  • 波特的五力分析

第18章 企业简介

• Merck & Co., Inc.
• Amgen Inc.
• F. Hoffmann-La Roche Ltd
• Pfizer Inc.
• Teva Pharmaceutical Industries Ltd.
• Sun Pharmaceutical Industries Ltd.
• Amneal Pharmaceuticals LLC
• Karyopharm
• Sumitomo Pharma Oncology, Inc
• Bristol-Myers Squibb Company

第19章 免责声明

Glioblastoma multiforme (GBM) is a type of aggressive brain cancer that develops from glial cells, which are cells that support and protect nerve cells in the brain. It is the most common and malignant form of primary brain tumor, accounting for about 15% of all brain tumors. The increasing prevalence of the glioblastoma multiforme is the major factor responsible for the market growth of the glioblastoma multiforme treatment market. For instance, As per the National Brain Tumor Society, GBM accounts for 49.1% of all primary malignant brain tumors. It is estimated that more than 10,000 people die from glioblastoma each year in the United States.

Glioblastoma Multiforme Treatment (GBM) Market is expected to grow at a strong CAGR of 8% during the forecast period owing to favorable governmental policies on brain cancer treatment. For instance, in December 2022, The Australian Brain Tumor Mission invested USD 136.66 million to support brain tumor research. The goal is to double survival rates and improve the quality of life for brain tumor patients.

Based on treatment, the market is segmented into surgery, radiation therapy, chemotherapy, targeted therapy, tumor treating Field (TTF) therapy, and immunotherapy. The radiation therapy segment acquired a major share in 2021. Radiation therapy uses high-energy radiation to kill cancer cells and shrink tumors. It is often used in combination with other treatments, such as surgery and chemotherapy, to improve the chances of success. The increasing incidence of brain tumors, the growing demand for personalized cancer treatment options, and the rising adoption of advanced radiation therapy technologies are the major attributing factor to the considerable share of radiation therapy in the GBM treatment market.

Based on the end-use, the market is segmented into hospitals, clinics, ambulatory surgical centers, and others. The clinics segment is expected to grow with the highest CAGR during the forecast period. The clinics in the GBM treatment market offer a variety of services, including imaging and diagnostic tests to confirm the presence of GBM, surgical procedures to remove tumors, radiation therapy to kill cancer cells, and chemotherapy to destroy cancer cells that have spread to other parts of the body are the main reason for the segmental growth.

For a better understanding of the market adoption of the industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, UK, France, Italy, Spain, Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, Australia, and Rest of Asia-Pacific), Rest of World. North America is a significant market for glioblastoma multiforme treatment. This is mainly due to the high prevalence of glioblastoma, along with the presence of the well-established infrastructure in the region attributes to the significant growth of the region in the glioblastoma multiforme treatment in the region. , with a growing number of people seeking out alternative and complementary therapies to supplement their conventional healthcare. Further, the region is also witnessing an increasing number of hospitals catering to integrative therapies also attributes to the growth of the market in the region. For instance, as per the National Brain Tumor Society, more than 13,000 Americans were diagnosed with glioblastoma multiforme in 2022.

Some of the major players operating in the market include: Merck & Co., Inc.; Amgen Inc.; F. Hoffmann-La Roche Ltd; Pfizer Inc.; Teva Pharmaceutical Industries Ltd.; Sun Pharmaceutical Industries Ltd.; Amneal Pharmaceuticals LLC; Karyopharm; Sumitomo Pharma Oncology, Inc; and Bristol-Myers Squibb Company.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Glioblastoma Multiforme Treatment (GBM) Market
• 2.2. Research Methodology of the Glioblastoma Multiforme Treatment (GBM) Market
• 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT (GBM) MARKET COVID-19 IMPACT

6 GLOBAL GLIOBLASTOMA MULTIFORME TREATMENT (GBM) MARKET REVENUE, 2020-2028F

7 MARKET INSIGHTS BY TREATMENT

• 7.1. Surgery
• 7.2. Radiation therapy
• 7.3. Chemotherapy
• 7.4. Targeted Therapy
• 7.5. Tumor Treating Field (TTF) Therapy
• 7.6. Immunotherapy

8 MARKET INSIGHTS BY END-USE

• 8.1. Hospitals
• 8.2. Clinics
• 8.3. Ambulatory Surgical Centers
• 8.4. Others

9 MARKET INSIGHTS BY REGION

• 9.1. North America Glioblastoma Multiforme Treatment (GBM) Market
  • 9.1.1. U.S.
  • 9.1.2. Canada
  • 9.1.3. Rest of North America
• 9.2. Europe Glioblastoma Multiforme Treatment (GBM) Market
  • 9.2.1. Germany
  • 9.2.2. UK
  • 9.2.3. France
  • 9.2.4. Italy
  • 9.2.5. Spain
  • 9.2.6. Rest of Europe
• 9.3. Asia-Pacific Glioblastoma Multiforme Treatment (GBM) Market
  • 9.3.1. China
  • 9.3.2. Japan
  • 9.3.3. India
  • 9.3.4. Australia
  • 9.3.5. South Korea
  • 9.3.6. Rest of APAC
• 9.4. Rest of the World Glioblastoma Multiforme Treatment (GBM) Market

10 GLIOBLASTOMA MULTIFORME TREATMENT (GBM) MARKET DYNAMICS

• 10.1. Market Drivers
• 10.2. Market Challenges
• 10.3. Impact Analysis

11 GLIOBLASTOMA MULTIFORME TREATMENT (GBM) MARKET OPPORTUNITIES

12 GLIOBLASTOMA MULTIFORME TREATMENT (GBM) MARKET TRENDS

13 DEMAND AND SUPPLY-SIDE ANALYSIS

• 13.1. Demand Side Analysis
• 13.2. Supply Side Analysis

14 VALUE CHAIN ANALYSIS

15 PRICING ANALYSIS

16 STRATEGIC INSIGHTS

17 COMPETITIVE SCENARIO

• 17.1. Competitive Landscape
  • 17.1.1. Porters Fiver Forces Analysis

18 COMPANY PROFILED

• 18.1. Merck & Co., Inc.
• 18.2. Amgen Inc.
• 18.3. F. Hoffmann-La Roche Ltd
• 18.4. Pfizer Inc.
• 18.5. Teva Pharmaceutical Industries Ltd.
• 18.6. Sun Pharmaceutical Industries Ltd.
• 18.7. Amneal Pharmaceuticals LLC
• 18.8. Karyopharm
• 18.9. Sumitomo Pharma Oncology, Inc
• 18.10. Bristol-Myers Squibb Company

19 DISCLAIMER